BioCryst Initiates Phase 1 Clinical Trial of Galidesivir
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first subject in a randomized, […]
Read more